Coronary Heart Disease Detection Test Merges Epigenetic and Genetic Biomarkers with Artificial Intelligence, Offering Remote and Scalable Deployment Capabilities Across the Nation CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer in AI-driven precision cardiovascular medicine tests, today announces the nationwide launch of PrecisionCHD™. This groundbreaking test marks a significant […]
Other News
Anumana Receives U.S. FDA Breakthrough Device Designation for its Cardiac Amyloidosis Algorithm
Developed in collaboration with Mayo Clinic, with support from Pfizer, this ECG-AI algorithm aims to aid physicians in earlier identification of cardiac amyloidosis CAMBRIDGE, Mass.–(BUSINESS WIRE)–Anumana, Inc., a leading AI-driven health technology company, has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its ECG-AI algorithm […]
Cleerly Wins 2023 Artificial Intelligence Breakthrough Award
Prestigious International Annual Awards Program Honors Standout AI and Machine Learning Solutions and Companies DENVER–(BUSINESS WIRE)–Cleerly, the company creating a new standard of care for heart disease, today announced that it has been named “Best Overall AI Solution” in the sixth annual AI Breakthrough Awards program conducted by AI Breakthrough, a […]
DiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke
MINNEAPOLIS–(BUSINESS WIRE)–DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today that the U.S. Food and Drug Administration (FDA) has removed the clinical hold placed on the investigational new drug application for its ReMEDy2 phase 2/3 clinical trial […]
DiaMedica Therapeutics Announces $37.5 Million Private Placement
MINNEAPOLIS–(BUSINESS WIRE)–DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases (“DiaMedica” or the “Company”), today announced it has entered into definitive agreements to sell its common shares in a private placement with accredited investors. The transaction is expected to […]
Surmodics Receives FDA Approval for the SurVeil™ Drug-Coated Balloon
Surmodics to receive $27 million milestone payment from Abbott EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the receipt of U.S. Food and Drug Administration (FDA) approval for the SurVeil™ drug-coated balloon (DCB). The […]
CorWave Announces Second Closing of Its Series C Funding at €61M to Finance Its First Industrial Deployment
CLICHY, France–(BUSINESS WIRE)–CorWave raised 61 million euros to fund its first industrial deployment and entry into clinical trials. SPI fund, managed by Bpifrance on behalf of the French Government as part of France 2030, and leading family controlled entrepreneurial groups were the main investors of this second closing. Founded in […]
Nuwellis Inc. Announces Pilot Agreement With DaVita Inc.
Supply Agreement to Pilot Ultrafiltration Therapy Services Offering in Select Markets MINNEAPOLIS, June 20, 2023 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced it has entered into a Supply and Collaboration Agreement with DaVita Inc. […]
RhythmScience Partners with MedAxiom
SAN FRANCISCO, June 20, 2023 /PRNewswire/ — RhythmScience, a leader in cardiac data management and services, announced their industry partnership with MedAxiom, the cardiovascular community’s premier source for organizational performance solutions. This significant collaboration signifies an important development for RhythmScience as they partner with MedAxiom to drive transformative changes in the cardiovascular […]
Cytokinetics Announces Start of MAPLE-HCM, a Phase 3 Clinical Trial of Aficamten Compared to Metoprolol in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
First Phase 3 Trial Evaluating Monotherapy with a Cardiac Myosin Inhibitor Compared to Monotherapy with a Beta Blocker in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy SOUTH SAN FRANCISCO, Calif., June 20, 2023 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM), a […]



